Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04166552
Other study ID # EHP-101-SS01
Secondary ID
Status Suspended
Phase Phase 2
First received
Last updated
Start date June 11, 2020
Est. completion date October 2024

Study information

Verified date September 2022
Source Emerald Health Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).


Description:

An interventional, double-blind, randomized, intracohort placebo-controlled design will be used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in 36 patients ≥ 18 and ≤ 74 years of age with documented dcSSc. There is a screening period of 28 days, 84 days treatment period, and 28 days follow-up.


Recruitment information / eligibility

Status Suspended
Enrollment 36
Est. completion date October 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria: - Patients male and female =18 years and =74 years at the time of consent; - American College of Rheumatology/ European League Against Rheumatism 2013 Criteria for SSc; dcSSc (skin thickening on upper arms, upper legs, or trunk); - Documented SSc for up to 6 years from the first non-Raynaud's phenomenon with a total mRSS of =15; - No new or increased doses of immunosuppressants medications within 3 months prior to Screening; - Effective method of contraception for participants and their partners. Exclusion Criteria: - Severe or unstable Systemic Sclerosis (SSc) or SSc with end-stage organ failure; - Patient with FVC <60%; - History of clinically significant medical condition or concurrent medical therapies that would exclude the patient, preclude participation in the clinical trial, influence response to study product, or interfere with study assessments; - History of gastrointestinal dysmotility requiring total parenteral nutrition or hospitalization within 6 months before Visit 1; - Any one of the following values for laboratory tests at screening: - Haemoglobin <9 g/dL; - Neutrophils <1.0 x 10^9/L; - Platelets <75 x 10^9/L; - Estimated creatinine clearance <50 mL/min according to the Cockcroft-Gault equation; - Serum transaminases >2.0 x upper normal limit; - Total bilirubin =1.5 x upper limit of normal.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Patients will be randomized to receive EHP-101 or Placebo
EHP-101 or placebo will be taken once a day
Patients will be randomized to receive EHP-101 or Placebo
EHP-101 or placebo will be taken twice a day

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide
Australia Royal Prince Alfred Hospital Camperdown
Australia Footscray Hospital Footscray
Australia Griffith University Gold Coast
Australia Fiona Stanley Hospital Murdoch
Australia Westmead Hospital Sydney
New Zealand Wellington Hospital Wellington
Puerto Rico Centro Reumatologico Caguas
Puerto Rico Mindful Medical Research San Juan
Puerto Rico University of Puerto Rico, Medical Sciences Campus San Juan
United States Central Florida Pulmonary Group Altamonte Springs Florida
United States Northwestern University Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States Care Access Research - Huntington Huntington Beach California
United States Pacific Arthritis Care Center Los Angeles California
United States UCLA Division of Rheumatology Los Angeles California
United States Life Clinical Trials Margate Florida
United States Novel Clinical Research Center Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Rutgers, The State University of New Jersey New Brunswick New Jersey
United States Yale University New Haven Connecticut
United States Arizona Arthritis & Rheumatology Associates, P.C. Phoenix Arizona
United States Inland Rheumatology Clinical Trials Upland California

Sponsors (1)

Lead Sponsor Collaborator
Emerald Health Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  New Zealand,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline of EHP-101 compared to placebo in Patient-Reported Outcomes Measurement Information system-29 Short (PROMIS)-29 Short measures self-reported physical, mental wellbeing. It consists of 29 questions. The questions are ranked on a 5-point Likert Scale. Day 85
Other Change from baseline of EHP-101 compared to placebo in 5 dimensions Itch Score 5-D Itch Score comprises the following 5 dimensions: degree, duration, direction, disability and distribution. The recall period is two weeks. Day 85
Other Change from baseline of EHP-101 compared to placebo in University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Questionnaire The UCLA SCTC GIT 2.0 has 7 multi-item scales: Reflux, Distension/Bloating, Diarrhea, Fecal Soilage, Constipation, Emotional Well-being, and Social Functioning and a total GIT score. All scales are scored from 0 [better health-related quality of life (HRQOL)] to 3 (worse HRQOL) except the diarrhea and constipation scales (ranges 0-2 and 0-2.5, respectively). The Total GIT Score, is developed by averaging 6 of 7 scales (excluding constipation). The recall period is one week. Day 85
Other Change from baseline of EHP-101 compared to placebo in Functional Assessment of Chronic Illness Therapy: Fatigue The FACIT Fatigue Scale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The composite score of all item will be used. The total score ranges from 0 to 52. The recall period is one week. Day 85
Other Change from baseline of EHP-101 compared to placebo in the European Quality of Life 5 Domain Questionnaire The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and as overall health using a "thermometer" visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Day 85
Other Quantitation of drug plasma levels at different timepoints to determine trough To determine trough level plasma concentrations of drug substance of EHP 101 Day 113
Primary Incidence and severity of Treatment Emergent Adverse Events This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments. Day 113
Secondary Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in modified Rodnan Skin Score (mRSS), Forced Vital Capacity (FVC) % predicted, physician and patient global assessments, and Scleroderma Health Assessment Questionnaire Disability Index (S-HAQ-DI). The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). Subjects are not considered improved (ACR CRISS score = 0) if they develop new: 1) renal crisis; 2) decline in FVC% predicted by 15% (relative) from baseline and confirmed after 1 month; or 3) left ventricular failure (systolic ejection fraction < 45%); or 4) new pulmonary artery hypertension on right heart catheterization requiring treatment. Day 85 and Day 113
Secondary Treatment effect of EHP-101 compared to placebo in modified Rodnan Skin Score The mRSS consists of an evaluation of patient's skin thickness rated by clinical palpation using a 0-3 scale (0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch the skin into a fold for each of 17 surface anatomic areas of the body: face, anterior chest, abdomen, and, with right and left sides of the body separately evaluated, the fingers, forearms, upper arms, thighs, lower legs, dorsum of hands and feet. Individual values are summed and defined as the total skin score. Total score is 0 to 51. Day 85 and Day 113
Secondary Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted Forced vital capacity (FVC) is a standard pulmonary function test used to quantify respiratory muscle weakness . FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100% Day 85 and Day 113
Secondary Treatment effect of EHP-101 compared to placebo in physician global assessment score The Physician Global Assessment of disease activity will be performed using a segmented numerical version of the visual analogue scale in which the physician selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by 2 verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The physician will select an integer to describe disease activity. The recall period is one week. Day 85 and Day 113
Secondary Treatment effect of EHP-101 compared to placebo in patient global assessments score The Patient Global Assessment will be performed with a segmented numerical version of the visual analogue scale in which the subject selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by two verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The subject will select an integer to describe disease activity. The recall period is one week. Day 85 and Day 113
Secondary Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index S-HAQ-DI includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are two or three questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The eight scores of the eight sections are summed and divided by 8. If one section is not completed by a subject, the summed score is divided by 7. As such, maximum scores can vary with a min of 0. The result is the DI, the disability index or functional disability index. The recall period is one week. Day 85 and Day 113
See also
  Status Clinical Trial Phase
Completed NCT02161406 - A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Completed NCT04137224 - Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) Phase 2
Not yet recruiting NCT04986605 - Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT02503644 - Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Phase 2
Recruiting NCT04781543 - A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Phase 2
Enrolling by invitation NCT05626751 - An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) Phase 2
Withdrawn NCT05098145 - A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis Phase 1/Phase 2
Terminated NCT04478994 - A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1
Completed NCT03198689 - Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis Phase 2
Terminated NCT04680975 - Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT00433186 - Mycophenolate Mofetil in Systemic Sclerosis Phase 1
Terminated NCT03919799 - KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Not yet recruiting NCT06375005 - Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis Phase 2
Recruiting NCT05270668 - Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Phase 2
Recruiting NCT05168215 - Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
Completed NCT04440592 - Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Phase 2
Recruiting NCT05149768 - Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Phase 2
Withdrawn NCT04138485 - Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) Phase 2